Business
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $10
About this update from Milestone Pharmaceuticals Inc.
[{"type":"image","alt":"Milestone Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Milestone Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":57,"url":"https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v8v9TEo7lCN2qTISQtxMtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/a3e01b195c1ef10ed327d66d987e808c","width":300,"height":57}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVT","length":114,"tagName":"p"}]},{"val":[{"type":"text","content":"Participants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placebo","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"CARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers ","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"$200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1","length":184,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host investor call and webcast at 8:30am ET today","length":60,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":643,"olType":false},{"type":"text","content":"MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and full year ending December 31, 2025, and provided corporate and regulatory updates. The main drivers of the fourth quarter and full year 2025 activities include the U.S. Food and Drug Administration (FDA) approval of CARDAMYST™ (etripamil) nasal spray for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults and product launch during this transformational year.","length":729,"tagName":"p"},{"type":"te...